Quintet Private Bank Europe S.A. Acquires 2,242 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Quintet Private Bank Europe S.A. grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 74,496 shares of the medical research company’s stock after buying an additional 2,242 shares during the quarter. Thermo Fisher Scientific makes up about 2.2% of Quintet Private Bank Europe S.A.’s investment portfolio, making the stock its 11th largest holding. Quintet Private Bank Europe S.A.’s holdings in Thermo Fisher Scientific were worth $37,069,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $25,000. FPC Investment Advisory Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. Pillar Financial Advisors LLC bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $30,000. Finally, Noble Wealth Management PBC bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $35,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.1%

Shares of TMO stock opened at $414.85 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The firm has a fifty day moving average price of $417.11 and a 200-day moving average price of $493.15. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $156.60 billion, a price-to-earnings ratio of 25.10, a PEG ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the previous year, the business earned $5.11 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on TMO. Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Citigroup lowered their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 23rd. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Finally, Argus dropped their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $605.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.